Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Olaparib + Pembrolizumab Maintenance in TNBC
NCT05174832Phase 2Unknown
- Sponsor
- Fudan University
- Start
- Sep 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of olaparib in triple-negative breast cancer (TNBC), sponsored by Fudan University. Status: unknown.
02
Drugs
olaparib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT05174832.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05174832.